| Dr Anupama Chennupati, MD | |
|
1634 Mistletoe Blvd, Fort Worth, TX 76104-4012 | |
| (817) 818-8433 | |
| (817) 423-7473 |
| Full Name | Dr Anupama Chennupati |
|---|---|
| Gender | Female |
| Speciality | Infectious Disease |
| Experience | 21 Years |
| Location | 1634 Mistletoe Blvd, Fort Worth, Texas |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023258043 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RI0200X | Internal Medicine - Infectious Disease | P5523 (Texas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Medical City Fort Worth | Fort worth, TX | Hospital |
| Wise Regional Health System | Decatur, TX | Hospital |
| Entity Name | Idexpertcare Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1598235194 PECOS PAC ID: 2860738234 Enrollment ID: O20190107002895 |
News Archive
A new study suggests that physiological stress in premature infants combined with separation from their mothers may have lasting effects into adulthood.
Reducing glucose metabolism dials down influenza viral infection in laboratory cell cultures, providing an entirely new approach for combating seasonal flu, according to research that will be presented on Sunday, Dec. 15, at the American Society for Cell Biology annual meeting in New Orleans.
A team of researchers from China and the University of Oregon have developed an approach for neuroscientists to study how meditation might provide improvements in a person's attention and response to stress.
Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has approved EYLEA (aflibercept) Injection for the treatment of diabetic retinopathy in patients with diabetic macular edema (DME). In 2014, the FDA granted EYLEA Breakthrough Therapy designation and Priority Review for the treatment of diabetic retinopathy in patients with DME.
ImThera Medical, Inc. today announced that it has concluded its Phase I and Phase II protocols for the European Pilot study of the aura6000, a neurostimulation device for treating Obstructive Sleep Apnea (OSA). Clinical trial results from the study will be announced at the American Thoracic Society's International Conference on May 16, 2011 in Denver, CO.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Anupama Chennupati, MD 912 Charleston Dr, Southlake, TX 76092-1536 Ph: (817) 818-8433 | Dr Anupama Chennupati, MD 1634 Mistletoe Blvd, Fort Worth, TX 76104-4012 Ph: (817) 818-8433 |
News Archive
A new study suggests that physiological stress in premature infants combined with separation from their mothers may have lasting effects into adulthood.
Reducing glucose metabolism dials down influenza viral infection in laboratory cell cultures, providing an entirely new approach for combating seasonal flu, according to research that will be presented on Sunday, Dec. 15, at the American Society for Cell Biology annual meeting in New Orleans.
A team of researchers from China and the University of Oregon have developed an approach for neuroscientists to study how meditation might provide improvements in a person's attention and response to stress.
Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has approved EYLEA (aflibercept) Injection for the treatment of diabetic retinopathy in patients with diabetic macular edema (DME). In 2014, the FDA granted EYLEA Breakthrough Therapy designation and Priority Review for the treatment of diabetic retinopathy in patients with DME.
ImThera Medical, Inc. today announced that it has concluded its Phase I and Phase II protocols for the European Pilot study of the aura6000, a neurostimulation device for treating Obstructive Sleep Apnea (OSA). Clinical trial results from the study will be announced at the American Thoracic Society's International Conference on May 16, 2011 in Denver, CO.
› Verified 8 days ago
Charles A Carlton, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 1622 8th Avenue, Suite 110, Fort Worth, TX 76104 Phone: 817-926-2561 Fax: 817-921-3708 | |
Paul J Garcia, DO Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 5701 Bryant Irvin Rd, Suite 302, Fort Worth, TX 76132 Phone: 817-294-9000 Fax: 817-294-9010 | |
Stevan A Gonzalez, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 1250 8th Ave, Suite 515, Fort Worth, TX 76104 Phone: 817-922-4675 Fax: 817-922-4645 | |
Jeremy Aaron Ross, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 800 W Magnolia Ave, Fort Worth, TX 76104 Phone: 817-759-7000 Fax: 817-759-7027 | |
Elie B Choufani, M.D. Infectious Disease Medicare: Medicare Enrolled Practice Location: 601 W Terrell Ave, Fort Worth, TX 76104 Phone: 817-852-8305 | |
Syed Hadi Jafri, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 1300 W Terrell Ave Fl 2, Fort Worth, TX 76104 Phone: 817-820-4906 Fax: 817-820-4815 | |
Cheryl K Mcdonald, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 1125 College Ave, Fort Worth, TX 76104 Phone: 817-810-9810 Fax: 817-810-9815 |